This information is intended for investors. Please read Advisory Information for Investors.

Welichem Biotech Inc. (TSX: WBI) is a world leader in the field of therapeutic drug discovery and development for the treatment of autoimmune and cell-proliferation diseases. We are pioneering the discovery and scientific understanding of the potential of metabolites from symbiotic microorganisms for the treatment of autoimmune and cell-proliferation diseases. The Company has discovered a series of metabolites, and their respective synthesized chemical compounds, that have commercial potential as therapeutic drugs. These discoveries, aimed at the treatment of unmet healthcare needs, are protected by patents worldwide for the sustained growth of our Company and the maximization of investors’ interests. Our strategy demonstrates our leadership in the discovery of new compounds, in our capability for sustained growth, and our interest in helping to ensure enhanced value for our shareholders.